Vor Biopharma Shares Outstanding History (VOR)
Vor Biopharma reported 96,800.49 shares outstanding at the end of fiscal 2025.
View full Vor Biopharma company overviewVor Biopharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 96,800.49 | 96,020.64 | +12312.71% |
| 2024 | 2024-12-31 | 779.85 | 779.85 | +11762422222.35% |
| 2023 | 2023-12-31 | 0 | 0 | +2.87% |
| 2022 | 2022-12-31 | 0 | 0 | +77.53% |
| 2021 | 2021-12-31 | 0 | 0 | +7260.26% |
| 2020 | 2020-12-31 | 0 | — | — |
Vor Biopharma quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 54.5M | 54.5M | +6934401.29% |
| Q1 2026 | 2026-03-31 | 2.7M | 2.7M | +6943901.36% |
| Q4 2025 | 2025-12-31 | 1.9M | 1.9M | +99301429.35% |
| Q3 2025 | 2025-09-30 | 1,128.365 | 1,128.312 | +2103370.80% |
| Q2 2025 | 2025-06-30 | 785.287 | 785.285 | +29408873.98% |
| Q1 2025 | 2025-03-31 | 39.016 | 39.016 | +29283813.72% |
| Q4 2024 | 2024-12-31 | 1.95 | 1.95 | +29405996.34% |
| Q3 2024 | 2024-09-30 | 0.054 | 0.054 | +810257.33% |
| Q2 2024 | 2024-06-30 | 0.003 | 0.003 | +40448.29% |
| Q1 2024 | 2024-03-31 | 0 | 0 | +1938.27% |
| Q4 2023 | 2023-12-31 | 0 | 0 | +2.87% |
| Q3 2023 | 2023-09-30 | 0 | 0 | +76.56% |
| Q2 2023 | 2023-06-30 | 0 | 0 | +79.79% |
| Q1 2023 | 2023-03-31 | 0 | 0 | +79.28% |
| Q4 2022 | 2022-12-31 | 0 | 0 | +77.53% |
| Q3 2022 | 2022-09-30 | 0 | 0 | +3.71% |
| Q2 2022 | 2022-06-30 | 0 | 0 | +1.68% |
| Q1 2022 | 2022-03-31 | 0 | 0 | +1.54% |
| Q4 2021 | 2021-12-31 | 0 | 0 | +7260.26% |
| Q3 2021 | 2021-09-30 | 0 | — | — |
| Q2 2021 | 2021-06-30 | 0 | — | — |
| Q1 2021 | 2021-03-31 | 0 | — | — |
| Q4 2020 | 2020-12-31 | 0 | — | — |
Vor Biopharma shares outstanding trends
Over the last five reported fiscal years, Vor Biopharma's shares outstanding moved from 0 to 96,800.49, a change of 96,800.49. The latest reported quarter, Q2 2026, shows 54.5M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vor Biopharma filings at SEC.gov ↗